TBE, and salmonellosis are likely to be majorly affected by climate change. CONCLUSIONS: Accelerating climate change carries a profound threat for the increased burden of infectious diseases worldwide. To attain the maximum disease prevention, an understanding of the ecology of infectious diseases must be developed in order to protect vulnerable populations, rather than focussing on single agent of disease.
OBJECTIVES:
To forecast and better understand the primary drivers of the incidence and prevalence of and mortality from drug sensitive and multidrug resistant tuberculosis (DS-TB and MDR-TB, respectively). METHODS: The Tuberculosis Simulation Model (TBSM) is a dynamic disease simulation model that uses historical and current disease incidence, treatment success rates, mortality, and transmission trends and can account for expected market events to estimate future DS-TB and MDR-TB incidence, prevalence and mortality in China. RESULTS: The model shows that between 2010 and 2050, DS-TB incidence, prevalence and mortality will decrease by 29%, 52% and 29%, respectively, whereas MDR-TB incidence, prevalence and mortality will fall by 3%, -11% and 10%, respectively. These reductions would be driven by an expected decrease in the pool of people with latent infection (brought about by improved cure rates which in turn reduces transmission rates) and reduced rate of progression from latent to active TB. CONCLUSIONS: Results from this model demonstrate considerable anticipated decreases in DS-TB and MDR-TB incidence and mortality in China over the next forty years; the decreases are much larger for DS-TB than for MDR-TB. Improvements in MDR-TB diagnosis and improved cure rates due to better MDR-TB treatments can likewise be expected to decrease MDR-TB incidence, prevalence and mortality over the long run. This adaptable TBSM tool has potential value in public health practice by forecasting outcomes of interventions and can also be useful for cost effectiveness modeling by country or by region by defining critical unmet need. 
INFECTION -Cost Studies PIN9 A MULTI-CENTER, RETROSPECTIVE, CHART REVIEW STUDY TO COMPARE DIRECT HEALTH CARE COSTS OF TREATMENT EXPERIENCED PATIENTS WITH HIV/AIDS BEFORE AND AFTER TRIPLE CLASS FAILURE IN THAILAND

OBJECTIVES:
To compare direct health care costs of treatment experienced patients with HIV/AIDS before and after triple class failure across participating centers. METHODS: The resource use data for eligible patients were collected two years before, and Ͼ 90 days following the date of triple class failure (TCF), which was between January 2002 and June 2008. The treatment failure was defined as virological failure to at least one drug from each of three classes (NRTI, NNRTI and PI). Costs of resource use at patient level were estimated by multiplying the number of resources used by the national micro-costing-based estimates. Comparisons of log-transformed expenditure data for the first 3, 6, 12 and 24 months before TCF with their corresponding intervals after TCF were carried out using linear mixed model. RESULTS: Of 42 patients recruited, mean age was 38 years and majority was male (66.7%). Outpatient visit expenditure after TCF was significantly 78.76Ϯ7.34, 78.26Ϯ13.28 and 683.00Ϯ90.21 baht higher than that before TCF during the first 3, 6 and 24 months respectively (PϽ0.001, ϭ0.003, and ϭ0.001, respectively). Compared with before TCF, expenditures on direct HIV lab tests (CD4/viral load/genotyping) after TCF were significantly 5133.74Ϯ661.80, 6907.23Ϯ742.23, 7505.29Ϯ981.76 and 9069.93Ϯ1219.37 Baht higher at the first 3, 6, 12 and 24 months, respectively (PϽ0.001, Ͻ0.001, Ͻ0.001, and ϭ0.004, respectively). Expenditures on antiretroviral medications after TCF were also higher although with significance only for the first 24 months (148414.06Ϯ32322.67 baht higher, Pϭ0.007) and with borderline significance for the first 3, 6 and 12 months. Finally, overall direct expenditures after TCF were significantly higher than those before TCF in all 4 periods. CONCLUSIONS: Once triple class failure occurred, overall direct expenditures increased significantly as early as 3 months and through 2 years of follow-up. The most dramatic increase was the costs associated with laboratory tests, especially genotyping, and outpatient visits. OBJECTIVES: Older adults are in an increasing risk of pneumococcal diseases, including meningitis and bacteremia (invasive pneumococcal disease, IPD), and pneumonia. The objective of this study was to estimate the clinical and economic burden of pneumococcal disease in adults Ն50 years of age in Taiwan. METHODS: Cases of hospitalized IPD and cases of hospitalized and outpatient pneumonia were obtained by ICD-9 codes from Taiwan's National Health Insurance Reimbursement Database from 2002-2009. Pneumococcal pneumonia was assumed to comprise 23.8% of all-cause pneumonia based on published literature. Data were stratified by age groups 50-64, 65-74, 75-84 and Ն85. Average incidence rates were calculated by dividing cases by age group and year specific population figures. Cost was extracted from the database for inpatient and outpatient cases; mortality estimation was based on hospital mortality. RESULTS: The average incidence per 100,000 person years was 2.4 for IPD, 278.8 for hospitalized pneumococcal pneumonia, and 1376.4 for outpatient pneumococcal pneumonia. Mortality was 12.2% for IPD and 10.0% for hospitalized pneumonia. Compared with adults 50-64 years of age, the incidence of pneumococcal hospitalization were 3.7 fold higher in those 65-74, 9.7 fold higher in 75-84 and 19.5 fold higher in those Ն85. The total number of hospitalizations increased by 20% from 2002 to 2009, largely attributable to population growth. In 2009, there were 16,711 pneumococcal hospitalizations, 103,302 outpatient visits, and 1,920 deaths, with a total cost of NT$ 2.92 billion. Hospitalized pneumococcal pneumonia was responsible for 94% of costs and 99% of mortality. CONCLUSIONS: The morbidity and mortality of pneumococcal disease increases sharply with advancing age, signaling an increasing public health problem in older adults as the population ages. Expanded utilization of cost-effective treatment and prevention efforts are warranted to alleviate the burden of pneumococcal diseases in Taiwan.
PIN10 EPIDEMIOLOGY AND ECONOMIC BURDEN OF PNEUMOMOCOCCAL DISEASE IN OLDER ADULTS IN TAIWAN
PIN11 ECONOMIC BURDEN OF INVASIVE PNEUMOCOCCAL DISEASES IN URBAN CHINA
Liu G 1 , Zhu L 2 , Li D 1 , Chen DE 1 , Deng J 1 , Dong P 3 , Shi Q 4 1 Peking University, Beijing, China, 2 Peking University, Beijing, Beijing, China, 3 Pfizer, Beijing, China, 4 Pfizer China, Shanghai, China OBJECTIVES: To estimate direct medical cost and productivity lost for invasive pneumococcal diseases in child under 2 in urban China. METHODS: Six health status contained pneumococcal meningitis (inpatient), pneumococcal septicemia (inpatient), pneumonia (all-cause, inpatient), pneumonia (all-cause, outpatient), mild otitis media (all-cause,outpatient) and sever otitis media (all-cause, outpatient )were considered. Age-specific cost was collected from electronic patient records (2010) from 14 hospitals in 7 cities in China. 2 hospitals in each city was selected (1 Children's Hospital, 1 Comprehensive Hospitals) and 7 field cities including Beijing, Guangzhou, Shenzhen, Wuhan, Xi'an, Chengdu and Shenyang were enrolled. Direct medical cost included registry fee, medications, and diagnostic tests fee, hospitalization expenditure. Cost of productivity lost were days for work absent of patient plus time consumed of infirmaries. In first part, weighted average method was used to calculate average direct medical cost. In second part, daily wage rate was applied to estimate cost of productivity lost. RESULTS: The average direct medical cost in all IPD cases (pneumococcal meningitis& pneumococcal septicemia) was 20,950 Yuan (95%CI: 4,489-101,003). Average 19 working days lost in patients' relatives for caring and costs of productivity lost was 1934 Yuan (95%CI: 532-6,412) per patient. CONCLUSIONS: IPD has a serious impact on life quality of child under 2 in Chinese urban areas and it could lead to severe economic burden.
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